In the meanwhile, Dot1l expression could stratify ccRCC patients by survival analyses in pT stage (1+2), Fuhrman grade (1+2) and SSIGN (0-3) subgroups, which might redefine risk stratification of ccRCC patients. Here, DOT1L is linked to nonpapillary renal cell carcinoma.